title: Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells.
abstract: human umbilical venous endothelial cells. 7E3 binding correlated with alphavbeta3-expression in all cell types. Integrin-mediated cell functions were analysed with adhesion and spreading assays on vitronectin. In human umbilical venous endothelial cells, these functions were mediated by alphavbeta3 and in human iliac arterial smooth muscle cells by alphavbeta5. In human umbilical venous smooth muscle cells, both vitronectin receptors were involved. Abciximab potently inhibited alphavbeta3-mediated cell adhesion and spreading. With tirofiban, no significant inhibition of vascular cell functions was observed. The present data demonstrate that vitronectin-cell interactions in vascular cells are mediated via two distinct integrin-receptors, alphavbeta3 and alphavbeta5. Abciximab, which solely inhibits alphavbeta3-mediated cell functions, may be particularly effective in human endothelium and in beta3-integrin expressing vascular smooth muscle cells.
authors.affiliation: Department of Medicine/Cardiology, Charité, Campus Virchow Klinikum, Humboldt Universität Berlin and Deutsches Herzzentrum Berlin, Augustenburger Platz 1, D-13353, Berlin, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Kintscher
authors.forename: K
authors.initials: K
authors.lastname: Kappert
authors.forename: G
authors.initials: G
authors.lastname: Schmidt
authors.forename: G
authors.initials: G
authors.lastname: Doerr
authors.forename: M
authors.initials: M
authors.lastname: Grill
authors.forename: B
authors.initials: B
authors.lastname: Wollert-Wulf
authors.forename: M
authors.initials: M
authors.lastname: Graefe
authors.forename: E
authors.initials: E
authors.lastname: Fleck
authors.forename: K
authors.initials: K
authors.lastname: Graf
mesh_terms: D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D005434:Flow Cytometry; D006801:Humans; D007083:Iliac Artery / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology*; D007150:Immunohistochemistry; D016023:Integrins / Q000096:biosynthesis; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D009842:Oligopeptides / Q000302:isolation & purification / Q000494:pharmacology; D019030:Receptors, Vitronectin / Q000096:biosynthesis / Q000187:drug effects* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014471:Umbilical Veins / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D019096:Vitronectin / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D016023:Integrins; D009842:Oligopeptides; D019030:Receptors, Vitronectin; D019096:Vitronectin; C064660:integrin alphaVbeta5; D014443:Tyrosine; D000077466:Tirofiban; D000077284:Abciximab